A trial fibrillation (AF) is the most common cardiac arrhythmia and it affects 2% to 3% of the global population.
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dabigatran. 12 The magnitude of risk associated with dabigatran in the Asian patient group remains unclear in a real-world clinical setting. Therefore, the objective of this study was to use the Taiwan National Health Insurance Research Database (NHIRD) to investigate the ischemic and bleeding outcomes associated with dabigatran in Asian patients with nonvalvular AF in comparison with warfarin.
Methods

Study Population
The National Health Insurance (NHI) system is a mandatory universal health insurance program, which offers comprehensive medical care coverage to all residents of Taiwan. The NHIRD is a national billing administrative database of healthcare services with >23 million enrollees, covering >99% of the population of Taiwan in 2014. 13 Informed consent was exempted because the original identification number of each patient in the NHIRD is encrypted and de-identified to protect their privacy using a consistent encrypting procedure so that it was feasible to link and continuously follow all of the claims belonging to the same patient within the NHIRD. We obtained approval of this study from the Institutional Review Board of Chang Gung Memorial Hospital.
Study Designs
A dynamic cohort with 2 study groups (dabigatran and warfarin) was used. A flowchart of the enrollment of the study cohort is shown in Figure 1 . From January 1, 1996, to December 31, 2013, a total of 304 252 new AF patients were identified. AF was identified by using the International Classification of Diseases (the Ninth Revision) Clinical Modification codes (427.31) registered by the clinician response for treatment. Among the 304 252 patients, 89 705 patients had at least 1 prescription filled for dabigatran or warfarin. The approval date of dabigatran was June 1, 2012, in Taiwan. Finally, we obtained 2 study groups, both from June 1, 2012, to December 31, 2013: dabigatran users (n=9940) and warfarin users (n=9913). The dabigatran group was further divided into 2 subgroups: dabigatran-only users (n=4402) and warfarin-experienced dabigatran users (n=5538). The index date was defined as the first date of prescribed dabigatran or warfarin after June 1, 2012, for each group. The follow-up period was from the index date until the first occurrence of any study outcome or the end of the study period (December 31, 2013), whichever came first.
Study Outcomes
We defined 6 study outcomes to determine the safety and efficacy for dabigatran and warfarin, as follows: ischemic stroke, acute myocardial infarction, intracranial hemorrhage, major gastrointestinal bleeding, all major bleeding events, and all-cause mortality. To avoid misclassification, the 6 study outcomes had to be a discharge diagnosis. Major gastrointestinal bleeding was defined as a hospitalized gastrointestinal bleeding event requiring transfusion. Intracranial hemorrhage was defined with the use of codes for atraumatic hemorrhage. [14] [15] [16] Major hospitalized bleeding events were defined as the total events of intracranial hemorrhage plus major gastrointestinal bleeding. The International Classification of Diseases (the Ninth Revision) Clinical Modification codes used to identify the 6 study outcomes are summarized in Table I in the online-only Data Supplement. Note that the same patient could have >1 study outcome and have the same study outcome many times during the study duration; only the study outcome that appeared first was counted because patients occurring the study outcomes (except for all-cause mortality) were managed differently afterward.
Covariates
Risk factors for cardiovascular events and bleeding and use of medication at baseline were referred to any claim records with the above diagnosis or medication code before the index date. A history of bleeding and hospitalization was confined to events within 12 months preceding the index date. A history of medicine prescription (antiplatelet agent, nonsteroid anti-inflammatory drug, steroid, or proton pump inhibitor) was confined to at least once within 3 months preceding the index date.
Statistical Analysis
The effects of dabigatran on the 6 study outcomes were estimated by using the propensity-score method, which is commonly used in epidemiologic studies for observational data. 17, 18 Propensity score is the predicted probability of being the dabigatran group using logistic regression to model the dabigatran group as a function of potential confounders of the grouping status and study outcomes. In time-to-event analyses (incident rate, log-rank test, and Cox's proportional hazard model), inverse probability of treatment weights of propensity scores was used to balance covariates across the 2 study groups. Incidence rates were estimated using the total number of study outcomes during the follow-up period divided by person-years at risk. The risk of study outcomes over time for dabigatran compared with warfarin (reference) was obtained using survival analysis (Kaplan-Meier method and log-rank test for univariate analysis and Cox proportional hazards regression for multivariate analysis). The balance of potential confounders at baseline (index date) between the 2 study groups was assessed using the absolute standardized mean difference rather than using statistical testing because balance is a property of the sample and not of an underlying population. The value of absolute standardized mean difference ≤0.1 indicates a negligible difference in potential confounders between the 2 study groups. 17 Statistical significance was defined as a P<0.05. All statistical analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
Results
A total of 9940 dabigatran-treated patients and 9913 warfarin-treated patients after June 1, 2012, were eligible for this study. Before propensity-score weighting, the dabigatran group was older, had a higher proportion of hypertension, hyperlipidemia, diabetes mellitus, stroke or transient ischemic attack history, a lower proportion of prescribing antiplatelet agents, and higher CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female) and HAS-BLED (hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, age 65 years or older, and antiplatelet drug or alcohol use) scores than the warfarin group. After propensity-score weighting, the 2 study groups were well balanced in all characteristics (all absolute standardized mean difference <0.1; Table 1 ).
The median follow-up period was 0.67 (0.34-1.03) years for dabigatran users and 0.73 (0.34-1.11) years for warfarin users. There were 526 study outcomes, including 205 ischemic strokes, 32 acute myocardial infarctions, 102 hospitalized major bleeding events, and 187 all-cause mortalities in the dabigatran group. Among the 102 hospitalized major bleeding events, there were 46 major gastrointestinal bleeding and 56 intracranial hemorrhage events. Compared with the warfarin group, the dabigatran group was associated with a significantly reduced risk of ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding events, and all-cause mortality (all P<0.0001) and a marginal decreased risk of acute myocardial infarction (HR, 0.67; P=0.0803; Table 2 ). There was no difference in major gastrointestinal bleeding between theshowed early separation of event-free curves for ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and all-cause mortality (Figures 2 and 3 ).
There were ≈88% (8772) and 12% (1168) of patients taking dabigatran 110 mg and 150 mg BID, respectively, in the dabigatran group (Table II in the online-only Data Supplement). Patients who took dabigatran 110 mg were older, had higher CHA 2 DS 2 -VASc and HAS-BLED scores, and a higher proportion had chronic kidney disease, hypertension, and antiplatelet agents prescription than patients who took dabigatran 150 mg. Dabigatran 110 mg was associated with a significantly lower risk of ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding events, and all cause-mortality than warfarin (all P<0.0001; Table 2 ). The dabigatran 150-mg users had similar outcomes as the 110-mg users, except that marginal effect in ischemic stroke was noted for dabigatran 150 mg compared with warfarin (HR, 0.61; P=0.0505). Both dabigatran 110 mg and 150 mg were not associated with an increased risk of major gastrointestinal bleeding and acute myocardial infarction when compared with warfarin.
The demographic and baseline medical characteristics of the dabigatran-only (n=4402) and warfarin-experienced dabigatran (n=5538) patients are summarized in Table III in the online-only Data Supplement. The dabigatran-only users were healthier with fewer comorbidities, lower CHA 2 DS 2 -VASc and HAS-BLED scores, and a higher prevalence of antiplatelet agent uses than the warfarin-experienced dabigatran users. Both the dabigatran-only and warfarin-experienced dabigatran users were associated with a lower risk of ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and all-cause mortality than warfarin users (Table 2 ). It is noted that the dabigatran-only users had a significantly lower risk of acute myocardial infarction than the warfarin users (HR, 0.43; P=0.0307; Table 2 ).
Stratified analysis by age showed that dabigatran decreased the risk of ischemic stroke, intracranial hemorrhage, and all hospitalized major bleeding events in the 65 to 74 years and 75 to 84 years age groups when compared with warfarin. Of note, dabigatran was associated with a lower risk of all-cause mortality in all age groups. Dabigatran did not significantly increase the risk 
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of major gastrointestinal bleeding and acute myocardial infarction when compared with warfarin in all age groups (Table 3) .
Discussion
This study is the first population-based investigation to analyze the risk of major cardiovascular events with a specific focus on Asian patients with non-valvular AF taking dabigatran. In this study, we found that dabigatran, in an Asian cohort with nonvalvular AF, with most patients taking 110 mg BID, was associated with a decrease in ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and all-cause mortality, but not major gastrointestinal bleeding and acute myocardial infarction when compared with warfarin. The dabigatran-only and warfarin-experienced dabigatran users both had a similar reduced risk of cardiovascular events, bleeding, and mortality when compared with warfarin users.
Our results for acute myocardial infarction and major gastrointestinal bleeding were different from those in the RE-LY trial. In the RE-LY trial, dabigatran 150 mg reduced the risk of ischemic stroke and intracranial hemorrhage, whereas increasing the risk of major gastrointestinal hemorrhage compared with warfarin in 18 113 analyzed patients. In addition, dabigatran showed a trend of increased myocardial infarction when compared with warfarin. There were only 1856 Asian patients (15.3%) taking dabigatran enrolled in the RE-LY trial. 6, 12, 19 Despite the similar distribution of patient medical histories and mean CHADS 2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack) score among Asian versus non-Asians, the efficacy and safety issue of dabigatran were not totally identical for Asian versus non-Asians in the RE-LY trial. 12, 19 Although Asian patients taking warfarin had CABG indicates coronary artery bypass graft; CHA 2 DS 2 -VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female; D, dabigatran; HAS-BLED, hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, age 65 years or older, and antiplatelet drug or alcohol use (Labile international normalized ratio could not be determined from claims and was excluded from our scoring.); NSAID, nonsteroid anti-inflammatory drugs; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; TIA, transient ischemic attack; and W, warfarin.
by guest on July 25, 2017 http://stroke.ahajournals.org/ Downloaded from considerably more time below the therapeutic range, there was a trend for more bleeding in Asian than in non-Asian patients. 12 For hemorrhagic stroke and total bleeding events, the rates in Asian patients taking warfarin were significantly higher than in non-Asian patients. In general, the absolute risk reduction of dabigatran was numerically greater in Asian than in non-Asian patients for myocardial infarction, ischemic stroke, hemorrhagic stroke, and all-cause death. 19 With regard to safety issues, dabigatran caused fewer bleeding episodes in Asian than in non-Asian patients for gastrointestinal bleeding, intracranial hemorrhage, and major bleeding episodes. 19 Of note, dabigatran decreased the risk of myocardial infarction CI indicates confidence interval; D, dabigatran; W, warfarin; and W→D, prescribed warfarin first and then switch to dabigatran. *Obtained using inverse probability of treatment weights of propensity scores. †Warfarin group was served as a reference inverse probability of treatment weights of propensity scores. and gastrointestinal bleeding when compared with warfarin in Asian patients, which was opposite to the finding in the nonAsian patient group. 12, 19 Therefore, our observation was compatible with the Asian subgroup analysis of the RE-LY trial. Our results also differed from those of a recent large observational study using Medicare data from the United States, which found an increased risk of gastrointestinal bleeding in 67 207 elderly patients (>65 years of age) treated with dabigatran when compared with those treated with warfarin. 8 Again, non-Asian patients comprised >95% of the total patients in the observation study, and it is not surprising for the study to draw a conclusion similar to that of the RE-LY trial.
In the present study, 44.2% of dabigatran users were warfarin-naïve patients, indicating that a novel oral anticoagulant, such as dabigatran, is considered to be a first-line oral anticoagulant in Taiwan. Our study indicated that the dabigatranonly users and warfarin-experienced dabigatran users had comparable outcomes with respect to reduced clinical events compared with warfarin users, which was in agreement with the results from the RE-LY study, where thromboembolic and bleeding events among previous warfarin users and warfarinnaïve patients were similar between groups. 20 Our results were different from those of a previous observational study that used Danish nationwide data, which found an increased risk of thromboembolism and bleeding in warfarin-experienced dabigatran users. 21 In our study, although the warfarin-experienced dabigatran users had more comorbidities and higher CHA 2 DS 2 -VASc and HAS-BLED scores than the naïve users (Table III in the online-only Data Supplement), the outcome of the study was not different between groups. With cautious interpretation because of the short follow-up period in our study, both dabigatran use in warfarin-naïve and warfarinexperienced patients seems to be a safe and effective option in the Asian cohort with a reduced risk of thromboembolic, bleeding events, and all-cause mortality compared with use of warfarin.
The RE-LY trial indicated that the favorable outcome of dabigatran over warfarin was attributable to the 150-mg dose, whereas the efficacy of dabigatran 110 mg was not different from warfarin. There were only 923 Asian patients who took dabigatran 110 mg in the RE-LY trial, and it was also found that dabigatran treatment at this dose did not reduce the risk of ischemic stroke and all-cause mortality compared with warfarin in this patient subgroup. 12, 19 Of note, the RE-LY study suggested that the dabigatran 110-mg dose was less effective when compared with the 150-mg dose, and as a result, this lower dose was not approved in the United States. 8 In contrast, our study represents the largest ever examination of the efficacy and safety of low-dose dabigatran with an enrollment of 8772 Asian patients, indicating that even dabigatran 110 mg significantly decreased the risk for ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and allcause mortality compared with warfarin in an Asian cohort. However, our data did not show an obvious advantage of 150 mg over 110 mg in further reducing the risk of ischemic stroke and all-cause mortality as demonstrated in the RE-LY trial. Warfarin group served as a reference. We cannot answer the question about why the results differed with certainty because of a limited number of prescriptions of dabigatran 150 mg in our Asian cohort (n=1168). There are several reasons why the clinical physicians prescribed the 110-mg dose instead of the 150-mg dose in our Asian patient group. It is thought that Asians are smaller in body size and have lower body mass index than non-Asians. 22 This observation was also supported by the subgroup analysis of the RE-LY trial, in which the Asians have substantially lower body weight than the non-Asians (66 versus 86 kg). 12 Even though the effect in efficacy of dabigatran was not evident in patients with a body mass index between 25 and 35, it may become relevant in underweight or obese patients. 23 , 24 As we know, the average body mass index of adults in Taiwan was found to be only 23.1, which was much lower than the mean value of adults in the United States (mean, 28.33), other Western countries, and the patients with AF enrolled in the RE-LY trial (mean, 28). 6, 25 Therefore, the clinical physicians in Taiwan may tend to prescribe a lower dose of dabigatran for their patients. The NHI system in Taiwan restricts dabigatran claims in AF patients >65 years of age with at least 1 risk factor or >75 years of age without any risk factors, which may potentially lead to selecting more patients with higher comorbidity (eg, elderly with chronic kidney or liver disease) when compared with the RE-LY trial. The clinical physicians may thus prescribe a lower dose of dabigatran for elderly patients to prevent potential bleeding events, as seen with the standard dose of dabigatran. Importantly, racial differences in warfarin sensitivity are evident, and it is noted that Asians have a particularly high risk for warfarin-related intracranial hemorrhage when compared with whites (HR, 4.06). 5 The concern of warfarin bleeding problems may also make physicians more conservative in prescribing other new anticoagulants as well. Additional studies enrolling more patients taking dabigatran 150 mg to clarify the possible beneficial profiles over the 110-mg dose in Asian patients are warranted.
In the current study, the increased risk of major gastrointestinal bleeding and acute myocardial infarction with dabigatran was not noted in any age group. The beneficial outcome of dabigatran on reduction of all-cause mortality was consistent in the 4 different age groups, in which the HRs of dabigatran versus warfarin were comparable. Thus, our data suggested that the efficacy and safety profiles of dabigatran were favorable in even very old Asian patients. This observation is different from that of a recent large cohort analysis of dabigatran, in which dabigatran was associated with an increased risk of major gastrointestinal bleeding and all-cause mortality in elderly patients aged ≥85 years in contrast to other age groups. 8 We should mention, however, that the decreased risk for intracranial hemorrhage was not obvious (HR, 0.64; P=0.1589), and there was an insignificantly increased risk for major gastrointestinal bleeding (HR, 1.60; P=0.1815) and a neutral risk for all hospitalized major bleeding (HR, 0.97; P=0.89) in our patients aged ≥85 years, and those results were opposite to the results in other younger age groups. The number of old patients was relatively limited in our study cohort (n=1516), which may have decreased the statistical power of determining the actual risk of intracranial and major gastrointestinal bleeding in the old patient group. A further study enrolling patients aged ≥85 years is necessary to clarify the actual efficacy and safety profiles for Asian patients of this age taking dabigatran.
The main advantage of the current study was the use of a nationwide data set with a sample of subjects; however, there were several limitations for this study. First, the NHIRD does not contain laboratory results so we could not evaluate the labile international normalized ratio and quality of warfarin in anticoagulation. Other important laboratory data like renal or liver function tests, serum cholesterol, habit of smoking or alcohol, body mass index, and other potential confounders could not be identified in the study cohort either. We had selected an extensive number of variables in our propensity-score method, and a close balance for those factors was achieved in the study. Similar covariables and the propensity-score method had been adopted as well in recent studies investigating the bleeding risks of dabigatran in non-Asian patients. 7, 8 Nevertheless, residual confounding by unmeasured factors cannot be excluded. Second, misclassification of AF, various ischemic and bleeding outcomes, and important comorbidities might jeopardize the findings of this study. Fortunately, the diagnostic accuracies of these factors in the Taiwan NHIRD have been validated before. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Furthermore, there have been several important studies using the same AF database in the NHIRD to investigate the risks of ischemic stroke and mortality in patients with AF with a variety of comorbidities and medications as well, indicating the consistency and reliability of the NHIRD. [37] [38] [39] [40] Third, our study did not examine switching dose in the dabigatran group during the follow-up period. As far as we know the switching of dabigatran dose is uncommon during the short follow-up time because there is no laboratory monitoring available to let the clinical physician adjust the medication dosage at each visit. The possible motivation that physicians may change the dabigatran dose is the occurrence of a clinical event (ie, to decrease or increase the dabigatran dose after bleeding or thomboembolic events occurred, respectively). Fourth, it is possible that the favorable results of dabigatran with regard to ischemic stroke, acute myocardial infarction, and all-cause mortality were partly caused by inadequate anticoagulation of warfarin, especially with less time in the therapeutic range of only 44% in Taiwanese patients. 12, [41] [42] [43] However, this cannot explain the lower risk of intracranial hemorrhage and neutral effect of major gastrointestinal bleeding with dabigatran than with warfarin at the same time. More importantly, whether warfarin was adequate for anticoagulation in the study, it reflects the real-world practice of physicians prescribing warfarin for Asian patients. Fifth, we could not differentiate between paroxysmal, persistent, and permanent AF or confirm whether AF was triggered by a single episode of acute illness based on this nationwide dataset. Finally, the follow-up period of dabigatran is limited (median, 0.67 years) because of unreleased whole-year data of the 2014 NHIRD until now, and the constancy of the HRs in a variety of clinical outcomes is unclear for a longer follow-up period. It would be interesting to know whether the major finding could be applicable to Asian patients with long-term follow-up.
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Conclusions
Dabigatran with a majority of patients taking a low dose of 110 mg BID was not associated with a higher risk of major gastrointestinal bleeding or acute myocardial infarction than warfarin in a nationwide Asian population with nonvalvular AF. Compared with warfarin, dabigatran 110-mg dose was associated with a reduced risk of ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and all causemortality in a large Asian cohort. Both those patients taking dabigatran without previous warfarin experience and those switching to dabigatran from warfarin benefited from dabigatran in both efficacy and safety issues when compared with warfarin. 
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